Pfizer shares rose early Tuesday due to higher than expected demand for its COVID vaccine, but quickly sunk 2.3% after ...
Pfizer's fourth quarter beat expectations on strong sales of its Covid vaccine and pill, bolstering its sales as it seeks to ...
CNBC on MSN10d
Pfizer tops earnings estimates as Covid product sales beat expectations and cost cuts pay offThe results cap off a critical year for Pfizer, which has been slashing costs as it recovers from the rapid decline of its ...
EXECUTIVE COMMENTARY Dr. Albert Bourla, Chairman and Chief Executive Officer, stated: “2024 was a strong year of execution and performance for Pfizer in which we met or exceeded our strategic and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results